|Bid||3.6600 x 1100|
|Ask||6.0000 x 1000|
|Day's Range||3.7500 - 4.0900|
|52 Week Range||2.2600 - 7.5000|
|Beta (3Y Monthly)||4.30|
|PE Ratio (TTM)||42.13|
|Earnings Date||Feb 6, 2018 - Feb 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.60|
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
Affimed (AFMD) exceeds earnings and sales estimates in the first quarter of 2019. The company also plans to focus its research and development investments.
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of 216.67% and 4163.60%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Alachua, Florida-based company said it had net income of 63 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 07, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 30, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
Applied Genetic Technologies (AGTC) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it has achieved enrollment milestones in two of its Phase 1/2 clinical trials. The company completed enrollment of the dose escalation portion of the achromatopsia (ACHM) CNGB3 trial, which is evaluating the safety and efficacy of its product candidate (rAAV2tYF-PR1.7-hCNGB3) for the treatment of ACHM caused by mutations in the CNGB3 gene.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! A look at the shareholders of Applied Genetic Technologies Corporation (NASDAQ:AGTC) can tell us which group is most powerful...
Applied Genetic Technologies (AGTC) is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases, explains Bill Mathews, small cap expert and editor of The Cheap Investor.
On a per-share basis, the Alachua, Florida-based company said it had a loss of 23 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Feb. 07, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of.
Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Jan. 02, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The direct benefit for Applied Genetic Technologies Corporation (NASDAQ:AGTC), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the Read More...
Applied Genetic Technologies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Applied Genetic Technologies Corp (NASDAQ: AGTC ), a biotech focused on adeno-associated virus-based gene therapies for the treatment of rare diseases, reported disappointing results from an X-linked retinoschisis ...
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stock hit 52-week high in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. ...
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...
- Results from XLRS study support general safety and tolerability of AGTC’s gene delivery platform but did not demonstrate signs of clinical activity at interim six-month time.